调节性树突状细胞在肾移植中的应用分析  

Analysis on application of regulatory dendritic cell in renal transplantation

作　　者：徐海燕[1] 徐仁芳[1] 何小舟[1] Xu Haiyan;Xu Renfang;He Xiaozhou(Department of Urology,the Third Affiliated Hospital of Soochow University,the First People's Hospital of Changzhou,Changzhou 213003,China)

机构地区：[1]苏州大学附属第三医院暨常州市第一人民医院泌尿外科,江苏常州213003

出　　处：《器官移植》2020年第5期622-628,共7页Organ Transplantation

基　　金：江苏省第十五批“六大人才高峰”项目(苏人社发[2018]240号);江苏省常州市卫健委科技项目(ZD201703)。

摘　　要：如何减少免疫抑制剂的应用是器官移植领域拟攻克的难题之一。细胞治疗被认为是替代免疫抑制剂、具有临床应用前景的有效解决方法,而调节性树突状细胞(DCreg)因其诱导免疫耐受特性受到重点关注。肾脏是实体、非免疫器官,肾移植术后受者机体和移植肾局部微环境的特殊性是否影响DCreg的应用是研究关注的焦点。本文从肾脏免疫的角度对DCreg在肾移植中的应用进行了分析。How to reduce the use of immunosuppressant is one of the difficult problems to be solved in the field of organ transplantation.Cell therapy is considered as an effective solution to replace immunosuppressant with a promising clinical application.Regulatory dendritic cell(DCreg)has attracted widespread attention due to its ability to induce immune tolerance.Kidney is a solid and non-immune organ.Whether the particularity of body and the local microenvironment of recipients after renal transplantation affects the application of DCreg is the focus of research.In this article,the application of DCreg in renal transplantation was analyzed from the perspective of renal immunity.

关 键 词：调节性树突状细胞 肾移植 细胞治疗 免疫抑制剂 免疫耐受 免疫应答 免疫调节 排斥反应 

分 类 号：R617[医药卫生—外科学] R329.2[医药卫生—临床医学]